On July 28th, the FDA approved the first interchangeable biosimilar, Semglee (long-acting insulin glargine), which implies that it can be automatically substituted at the pharmacy counter. This will usher in more competition into the insulin glargine market.
Approval Of First Interchangeable Biosimilar, Semglee, Is Sign Of An Improving U.S. Biosimilars Market, Despite Challenges
